Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.

BACKGROUND: Plasma-derived (pd) or recombinant (r) therapeutic factor VIII proteins (FVIIIs) are infused to arrest/prevent bleeding in patients with hemophilia A (PWHA). However, FVIIIs are neutralized if anti-FVIII-antibodies (inhibitors) develop. Accumulating evidence suggests that pdFVIIIs with von Willebrand factor (VWF) are less immunogenic than rFVIIIs and that distinct rFVIIIs are differentially immunogenic. Since inhibitor development is T-helper-cell-dependent, human leukocyte antigen (HLA)-class-II (HLAcII) molecules constitute an important early determinant. OBJECTIVES: Use dendritic cell (DC)-protein processing/presentation assays with mass-spectrometric and peptide-proteomic analyses to quantify the DP-bound, DQ-bound, and DR-bound FVIII-derived peptides in individual HLAcII repertoires and compare the immunogenic potential of six distinct FVIIIs based on their measured peptide counts. PATIENTS/METHODS: Monocyte-derived DCs from normal donors and/or PWHA were cultured with either: Mix-rFVIII, a VWF-free equimolar mixture of a full-length (FL)-rFVIII [Advate® (Takeda)] and four distinct B-domain-deleted (BDD)-rFVIIIs [Xyntha® (Pfizer), NovoEight® (Novo-Nordisk), Nuwiq® (Octapharma), and Afstyla® (CSL Behring GmBH)]; a pdFVIII + pdVWF [Beriate® (CSL Behring GmBH)]; Advate ± pdVWF; Afstyla ± pdVWF; and Xyntha + pdVWF. RESULTS: We showed that (i) Beriate had a significantly lower immunogenic potential than Advate ± pdVWF, Afstyla - pdVWF, and Mix-rFVIII; (ii) distinct FVIIIs differed significantly in their immunogenic potential in that, in addition to (i), Afstyla + pdVWF had a significantly lower immunogenic potential than Beriate, while the immunogenic potential of Beriate was not significantly different from that of Xyntha + pdVWF; and (iii) rFVIIIs with pdVWF had significantly lower immunogenic potentials than the same rFVIIIs without pdVWF. CONCLUSIONS: Our results provide HLAcII peptidomic level explanations for several important clinical observations/issues including the differential immunogenicity of distinct FVIIIs and the role of HLAcII genetics in inhibitor development.

"Heavy fluorous" cyclopentadienes and cyclopentadienyl complexes with three to five ponytails: facile syntheses from polybromocyclopentadienyl complexes, phase properties, and electronic effects.

The reactions between [(eta5-C5H(5-x)Br(x))M(CO)3] (M = Re, Mn; x = 1, 3, 4, 5) and [IZn[(CH2)(n)R(f8)]] (n = 2, 3; R(f8) = (CF2)7CF3) in the presence of [Cl2PdL2] catalysts give the title complexes [[eta5-C5H(5-x)[(CH2)(n)R(f8)]x]M(CO)3]. In the case of x = 5, the major product is actually [[eta5-C5H[(CH2)(n)R(f8)]4]M(CO)3], in which one of the bromides has been substituted by hydride. Minor amounts of multiple hydride substitution products are formed, all of them readily separable on fluorous silica gel. Irradiation of the manganese complexes in CF3C6H5/MeOH/ether gives uncoordinated cyclopentadienes, which can be deprotonated and reattached to other metals. Partition coefficients have been measured (CF3C6F11/toluene): complexes with three or more ponytails are highly fluorophilic, with values of > 99.8: < 0.2. The IR [symbol: see text]CO bands have been used to probe the inductive effects of the ponytails at the metal centers.

Synthesis, structure, and reactivity of fluorous phosphorus/carbon/phosphorus pincer ligands and metal complexes.

Reactions of the diphosphine 1,3-C6H4(CH2PH2)2 and fluorous alkenes H2C=CHR(fn)(R(fn)=(CF2)(n-1)CF3; n = 6, 8) at 75 degrees C in the presence of AIBN give the title ligands 1,3-C6H4(CH2P(CH2CH2R(fn))2)2(3-R(fn)) and byproducts 1,3-C6H4(CH3)(CH2P(CH2CH2R(fn))2)(4-R(fn)) in 1 : 3 to 1 : 5 ratios. Workups give -R(fn) in 4--17% yields. Similar results are obtained photochemically. Reaction of 1,3-C6H4(CH2Br)2 and HP(CH2CH2R(f8))2 (5) at 80 degrees C (neat, 1 : 2 mol ratio) gives instead of simple substitution the metacyclophane [1,3-C6H4(CH2P(CH2CH2R(f8))2 CH2-1,3-C(6)H(4)CH(2)P[lower bond 1 end](CH2CH2R(f8))2C[upper bond 1 end]H2](2+)2Br-, which upon treatment with LiAlH(4) yields 3-R(f8)(20%), 4-R(f8), and other products. Efforts to better access 3-R(f8), either by altering stoichiometry or using various combinations of the phosphine borane (H3B)PH(CH2CH2R(f8))2 and base, are unsuccessful. Reactions of 3-R(fn) with Pd(O2CCF3)2 and [IrCl(COE)2]2(COE=cyclooctene) give the palladium and iridium pincer complexes (2,6,1-C6H3(CH2 P(CH2CH2R(fn))(2)(2)Pd(O2CCF3)(10-R(fn); 80-90%) and (2,6,1-C6H3(CH2P(CH2CH2R(f8))2)2)Ir(Cl)(H)(11-R(f8); 29%), which exhibit CF3C6F(11)/toluene partition coefficients of >96 : <4. The crystal structure of 10-R(f8) shows CH2CH2R(f8) groups with all-anti conformations that extend in parallel above and below the palladium square plane to create fluorous lattice domains. NMR monitoring shows a precursor to 11-R(f8) that is believed to be a COE adduct.

Convenient syntheses of "heavy fluorous" cyclopentadienes and cyclopentadienyl complexes with three to five ponytails.

Reactions of (eta5-C5H(5-x)Brx)M(CO)3(M = Re, Mn; x= 1, 3, 4, 5) and IZn(CH2)2R(f8) in the presence of Cl2PdL2 catalysts give the title complexes (eta5)-C5H(5-x)(CH2)2R(f8)x)M(CO3), accompanied in the case of x= 5 by hydride-transfer byproducts. Extremely high fluorophilicities are realized, and the cyclopentadienyl ligands are readily detached (hnu) from the manganese complexes.